Australia markets closed

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
17.500.00 (0.00%)
At close: 11:29AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close17.50
Open17.80
Bid0.00 x 0
Ask0.00 x 0
Day's range17.50 - 17.50
52-week range15.96 - 26.29
Volume16
Avg. volume1,491
Market cap10.78B
Beta (5Y monthly)0.17
PE ratio (TTM)60.34
EPS (TTM)0.29
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date03 June 2021
1y target estN/A
  • PR Newswire

    Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening

    Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and the development of innovative diagnostic solutions, today announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.

  • Motley Fool

    Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

    On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.

  • GlobeNewswire

    GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

    SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs. The article demonstrates the potential of GigaGen’s machine learning